Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

NCT06972641 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

126

Enrollment

OTHER

Sponsor class

Conditions

AML
MDS

Interventions

DRUG: Decitabine
DRUG: Sorafenib (BAY-43-9006)，giritinib
DRUG: Avastinib
DRUG: Venetoclax;Selenisol

Sponsor

Ruijin Hospital